• Huck-Joo Tan, Sanjiv Mahadeva, Jayaram Menon, Wai Kiat Ng, Imran Zainal Abidin, Francis Kl Chan, Khean-Lee Goh, Malaysian Society of Gastroenterology & Hepatology, and National Heart Association of Malaysia.
• Sunway Medical Centre, Selangor, Malaysia. hucktan@hotmail.com
• J Dig Dis. 2013 Jan 1;14(1):1-10.

AbstractThe working party statements aim to provide evidence and guidelines to practising doctors on the use of antiplatelet therapy and proton pump inhibitors (PPIs) in patients with cardiovascular risk as well as those at risk of gastrointestinal (GI) bleeding. Balancing the GI and cardiovascular risk and benefits of antiplatelet therapy and PPIs may sometimes pose a significant challenge to doctors. Concomitant use of anti-secretory medications has been shown to reduce the risk of GI bleeding but concerns have been raised on the potential interaction of PPIs and clopidogrel. Many new data have emerged on this topic but some can be confusing and at times controversial. These statements examined the supporting evidence in four main areas: rationale for antiplatelet therapy, risk factors of GI bleeding, PPI-clopidogrel interactions and timing for recommencing antiplatelet therapy after GI bleeding, and made appropriate recommendations.© 2012 The Authors. Journal of Digestive Diseases © 2012 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Wiley Publishing Asia Pty Ltd.

18 keywords...

hide…